Press releases
- Agilent to Announce First-Quarter Fiscal Year 2023 Financial Results Feb. 28
- Agilent to Collaborate with Quest Diagnostics to Extend Access to the Agilent Resolution ctDx FIRST Liquid Biopsy Test
- Agilent Included in Just Capital’s 2023 List of Most Just Companies
- Agilent Authorizes $2 Billion Share Repurchase Program
- Agilent Investing $725 Million to Expand State-of-the-Art Manufacturing Capacity for Production of Nucleic Acid-Based Therapeutics
- Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
- Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
- Agilent to Present at Goldman Sachs and J.P. Morgan Healthcare Conferences
- Agilent Resolution ctDx FIRST Receives FDA Approval as a Liquid Biopsy Companion Diagnostic Test for Advanced Non-small Cell Lung Cancer
- Agilent Again Named to Newsweek’s List of America’s Most Responsible Companies
More ▼
Key statistics
On Monday, Agilent Technologies Inc (AG8:BRN) closed at 126.25, 0.00% below its 52-week high of 126.25, set on Mar 28, 2022.
52-week range
Markit short selling activity
Open | 126.25 |
---|---|
High | 126.25 |
Low | 126.25 |
Bid | 126.46 |
Offer | 126.87 |
Previous close | 126.25 |
Average volume | -- |
---|---|
Shares outstanding | 295.86m |
Free float | 294.19m |
P/E (TTM) | 36.93 |
Market cap | 45.71bn USD |
EPS (TTM) | 4.18 USD |
Annual div (ADY) | 0.8321 CHF |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Dec 30 2022 |
Div pay-date | Jan 25 2023 |
Data delayed at least 15 minutes, as of Mar 28 2022.
More ▼